Multi-System Inflammatory Syndrome in Children in Association with COVID-19


Multi-System Inflammatory Syndrome in Children in Association with COVID-19.

View Article

Simpson JM, Newburger JW.
Circulation. 2020 Jun 11. doi: 10.1161/CIRCULATIONAHA.120.048726. Online ahead of print.
PMID: 32525700

Take Home Points:

  • Multisystem inflammation in children (MIS-C) is a newly recognized syndrome mimicking Kawasaki disease in some aspects of clinical presentation and clinical course temporally associated with COVID-19 infection.
  • Multisystem inflammatory syndrome in children shares similarities with atypical Kawasaki disease, however, clinical criteria of diagnosis of Kawasaki disease was not fulfilled.
  • Coronary dilation including giant aneurysm can happen.
  • Markers of inflammation and cardiac involvement—including troponin I, brain natriuretic peptide, D-dimer, C-reactive protein, and interleukin 6—were all elevated.
  • Left ventricular systolic dysfunction requiring ionotropic support is common.
  • Additional studies are needed to determine the longer-term impact of MIS-C on myocardial function and coronary arteries.
  • The optimal treatment for MIS-C is uncertain. Patients are often treated with immunomodulatory therapy including intravenous immunoglobulin and steroids. In more severe cases e anakinra, infliximab, or tocilizumab has been used.

Dr Shaji Menon

Comment from Dr. Shaji Menon (Salt Lake City, Utah), section editor of Pediatric Cardiology Journal Watch:  This article is an excellent commentary on the above discussed original article by Simpson and Newburger.

case definitions for multisystem inflammatory syndrome in children


Dive straight into the feedback!
Login below and you can start commenting using your own user instantly